Brainomix appoints Khush F. Mehta as chair to support global expansion and commercial growth
OXFORD, England and CHICAGO, May 21, 2025 -- Brainomix, a global leader in AI-powered imaging solutions in stroke and lung fibrosis, today announced the appointment of Khush F. Mehta as Chair of the Board. He succeeds Professor Jacqueline ('Jackie') Hunter CBE, who has served as Chair for the past five years.
Khush brings more than two decades of global strategic and operational leadership in healthcare, having recently served as Chairman of Arterys, a pioneer of AI in medical imaging, which was acquired by Tempus AI in 2022. Prior to this, Khush was the Chief Strategy Officer at Siemens Healthcare, the head of the company for Asia Pacific and also held various leadership roles in the US and Germany. He has an MBA from the Yale School of Management and a Master's degree in Commerce and Financial Management from Sydenham College in Mumbai.
Based in the US, Khush will support Brainomix's continued internationalization, helping guide its next phase of growth as it deepens its presence in the US and explores new markets for its AI imaging solutions in stroke and lung fibrosis.
The appointment follows the company's recent £14 millionSeries C investment, which provides the resources to accelerate commercial expansion of its stroke platform in the US and international markets. Brainomix recently secured a major FDA clearance for a novel and patented feature in its Brainomix 360 platform, reinforcing its position as a leader in the AI imaging space.
Dr Michalis Papadakis, CEO and Co-Founder at Brainomix, said:
We are delighted to welcome Khush as Chair at a pivotal growth stage for Brainomix. His extensive leadership across international markets, coupled with his deep expertise in healthcare AI, makes him an ideal Chair to help navigate our further global expansion. As we scale our impact across stroke and lung disease, his guidance will be invaluable in driving forward our mission to improve outcomes for patients worldwide.
Khush F. Mehta, Chair of Brainomix, said:
Brainomix has developed one of the most clinically impactful AI platforms, with demonstrative real-world data showing a transformative effect on stroke care. I'm honored to support the company in its next chapter, as it expands into new geographies and therapeutic areas. With a strong foundation in Europe and an growing footprint in the US, Brainomix is uniquely positioned to become a global leader in healthcare AI.
